文献速递肝病消化道肿瘤与早癌

全基因组siRNA筛选揭示HBV感染前病毒与抗病毒宿主因子

A genome-wide siRNA screen identifies previously unknown proviral and antiviral host factors in HBV infection.
PubMed 文献 · J Hepatol · 2025-11-26

研究在HepG2-NTCP细胞中进行全基因组siRNA筛选,以AlphaLISA检测细胞内HBV核心抗原和e抗原为读出,鉴定并验证HBV感染相关宿主因子。验证确认NCOA5和CHD4为前病毒宿主因子,NRAS为抗病毒因子,并在21例HBV相关肝细胞癌组织及AAV-HBV小鼠模型中分析。

要点

  • NCOA5和CHD4为HBV复制必需的前病毒宿主因子。
  • NRAS为抗病毒因子,其敲低通过升高HNF4α增强HBV转录。
  • 研究揭示HNF4α、cccDNA表观调控和细胞周期相关机制。

核心结论

  • NCOA5和CHD4是HBV感染的关键前病毒宿主因子,NRAS是调控HBV复制的有效抗病毒因子。

研究设计与样本

  • 在HepG2-NTCP细胞中进行全基因组siRNA筛选,以AlphaLISA检测细胞内HBV核心抗原和e抗原为读出。
  • 在肝癌细胞系或原代人肝细胞中通过敲低、过表达和敲除进行体外验证。
  • 分析21例HBV相关肝细胞癌患者肿瘤与非肿瘤组织的基因表达。
  • 使用AAV-HBV小鼠模型进行体内评估及靶点调控。

主要发现

  • 敲低NCOA5和CHD4显著降低HBV复制。
  • NRAS被鉴定为抗病毒因子。
  • NCOA5可能通过雌激素受体和HNF4α轴发挥作用,CHD4调控cccDNA组蛋白修饰。
  • NRAS敲低通过升高HNF4α表达和诱导细胞周期阻滞增强HBV转录。
  • HBV相关肝细胞癌组织中常见RAS过度激活,可能解释该组织中观察到的HBV复制受限。

临床怎么用

  • NCOA5、CHD4和NRAS可作为开发抗HBV治疗策略的候选宿主靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Hepatitis B virus (HBV) extensively exploits host cellular machinery for productive infection. This study aimed to comprehensively identify and validate host factors critical for HBV infection using a functional genomics approach. METHODS: A whole-genome small-interfering RNA screen was performed in HepG2-NTCP cells, utilizing high-throughput AlphaLISA detection of intracellular HBV core and e antigens as the readout. Selected genes underwent rigorous multi-tiered validation: in vitro assessment of viral infection/replication via knockdown, overexpression, and knockout in hepatoma cell lines or primary human hepatocytes; analysis of gene expression in tumor/non-tumor tissues from 21 patients with HBV-related hepatocellular carcinoma; and in vivo evaluation using an AAV-HBV mouse model with target modulation. RESULTS: Validation confirmed nuclear receptor coactivator 5 (NCOA5) and chromodomain-helicase-DNA-binding protein 4 (CHD4) as essential proviral host factors; their knockdown significantly reduced HBV replication. Conversely, neuroblastoma RAS (NRAS) was identified as an antiviral factor. Mechanistically, NCOA5 likely operates via the estrogen receptor and hepatocyte nuclear factor 4 alpha (HNF4α) axis, while CHD4 modulates cccDNA histone modifications. NRAS knockdown enhanced HBV transcription by elevating HNF4α expression and inducing cell cycle arrest, which may explain the observed restriction of HBV replication in HBV-associated hepatocellular carcinoma tissues, where RAS hyperactivation frequently occurs. CONCLUSIONS: This study identifies NCOA5 and CHD4 as crucial proviral cofactors and NRAS as a potent antiviral factor regulating HBV replication. The findings highlight HBV's profound host dependence, uncover specific molecular mechanisms (involving HNF4α, epigenetic regulation of cccDNA, and cell cycle), and reveal validated host targets for potential therapeutic strategies against HBV infection. IMPACT AND IMPLICATIONS: Hepatitis B virus (HBV) needs human liver cell machinery to infect and multiply. We used large-scale genetic screening to find human proteins that either help or block HBV infection. We discovered two key proteins (NCOA5 and CHD4) that help HBV replicate, and one protein (NRAS) that blocks it. We confirmed these findings in human liver cells and mice. Understanding how these proteins control HBV (through regulating viral transcription, modifying viral DNA, or affecting cell growth) reveals potential new targets for developing better treatments against this serious liver infection.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Cheng X, Xia Y, Li C, et al. A genome-wide siRNA screen identifies previously unknown proviral and antiviral host factors in HBV infection. J Hepatol. 2025. PMID: 41314348. doi:10.1016/j.jhep.2025.11.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。